Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Gene | FGFR2 |
Variant | fusion |
Impact List | fusion |
Protein Effect | unknown |
Gene Variant Descriptions | FGFR2 fusion indicates a fusion of the FGFR2 gene, but the fusion partner is unknown. |
Associated Drug Resistance | |
Category Variants Paths |
FGFR2 mutant FGFR2 rearrange FGFR2 fusion |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02608125 | Phase I | PRN1371 | A Dose Escalation Study in Solid Tumors and a Dose Expansion Study of PRN1371 in Adult Patients With Metastatic Urothelial Carcinoma | Terminated | USA | ESP | 0 |
NCT05267106 | Phase II | Pemigatinib | Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations (FIGHT-209) | Active, not recruiting | USA | NLD | ITA | GBR | FRA | ESP | DEU | 2 |
NCT05948475 | Phase III | Tinengotinib | Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma (FIRST-308) | Recruiting | USA | ITA | GBR | FRA | ESP | DEU | BEL | AUT | 4 |
NCT04083976 | Phase II | Erdafitinib | A Study of Erdafitinib in Participants With Advanced Solid Tumors and Fibroblast Growth Factor Receptor (FGFR) Gene Alterations (RAGNAR) | Active, not recruiting | USA | ITA | GBR | FRA | ESP | DEU | BEL | AUS | 7 |
NCT02052778 | Phase Ib/II | Futibatinib | A Study of TAS-120 in Patients With Advanced Solid Tumors | Completed | USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | AUS | 4 |
NCT03834220 | Phase II | Debio 1347 | Basket Trial in Solid Tumors Harboring a Fusion of FGFR1, FGFR2 or FGFR3- (FUZE Clinical Trial) | Terminated | USA | NLD | GBR | FRA | ESP | AUT | AUS | 16 |
NCT05174650 | Phase II | Atezolizumab + Derazantinib | Treatment of Atezolizumab and Derazantinib in Patients With Advanced iCCA With FGFR2 Fusions/Rearrangements | Recruiting | DEU | 0 |
NCT04972253 | Phase I | Infigratinib | Phase I BLASST-3 Trial ((BLASST)-3) | Withdrawn | 0 | |
NCT04045613 | Phase Ib/II | Derazantinib Atezolizumab + Derazantinib | Derazantinib and Atezolizumab in Patients With Urothelial Cancer (FIDES-02) | Completed | USA | ITA | GBR | FRA | ESP | DEU | CAN | AUT | AUS | 5 |
NCT04088188 | Phase I | Cisplatin + Gemcitabine + Pemigatinib Cisplatin + Gemcitabine + Ivosidenib | Gemcitabine and Cisplatin With Ivosidenib or Pemigatinib for the Treatment of Unresectable or Metastatic Cholangiocarcinoma | Terminated | USA | 0 |
NCT05316155 | Phase I | Erdafitinib | Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer | Recruiting | USA | NLD | ESP | DEU | 1 |
NCT06160752 | Phase I | TYRA-200 | Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene Alterations (SURF201) | Recruiting | USA | 0 |
NCT02160041 | Phase II | Infigratinib | BGJ398 for Patients With Tumors With FGFR Genetic Alterations | Terminated | USA | 0 |
NCT04526106 | Phase I | RLY-4008 | REFOCUS: A First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With ICC and Other Advanced Solid Tumors | Active, not recruiting | USA | NLD | ITA | GBR | FRA | ESP | DEU | AUS | 5 |
NCT05216120 | Phase II | Pemigatinib | Pemigatinib in Subjects With Adenosquamous Carcinoma of the Pancreas | Withdrawn | USA | 0 |
NCT04172675 | Phase II | Erdafitinib Gemcitabine Mitomycin C | A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) | Active, not recruiting | USA | ITA | GBR | FRA | ESP | DEU | BEL | AUS | 9 |
NCT03230318 | Phase II | Derazantinib | Derazantinib in Subjects With FGFR2 Gene Fusion-, Mutation- or Amplification- Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma (FIDES-01) | Completed | USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | 3 |
NCT05244551 | Phase I | ABSK061 | A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK061 in Patients With Advanced Solid Tumors | Recruiting | USA | 1 |
NCT02393248 | Phase Ib/II | Cisplatin + Gemcitabine + Pemigatinib Docetaxel + Pemigatinib Pemigatinib + Retifanlimab Pemigatinib + Trastuzumab Epacadostat + Pembrolizumab | Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101) | Terminated | USA | 1 |
NCT02546661 | Phase I | Danvatirsen + Durvalumab Durvalumab + Selumetinib AZD4547 Durvalumab + Olaparib Durvalumab AZD4547 + Durvalumab Durvalumab + Vistusertib Adavosertib + Durvalumab | Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer (BISCAY) | Active, not recruiting | USA | GBR | FRA | ESP | CAN | 0 |
NCT02872714 | Phase II | Pemigatinib | A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Urothelial Carcinoma - (FIGHT-201) | Completed | USA | NLD | ITA | GBR | FRA | ESP | DEU | BEL | 3 |
NCT02265341 | Phase II | Ponatinib | Ponatinib Hydrochloride in Treating Patients With Advanced Biliary Cancer With FGFR2 Fusions | Completed | USA | 0 |
NCT06302621 | Phase I | Afatinib + Pemigatinib | Pemigatinib + Afatinib in Advanced Refractory Solid Tumors | Recruiting | USA | 0 |
NCT02925234 | Phase II | Palbociclib Ribociclib Lenvatinib Ipilimumab + Nivolumab Trametinib Crizotinib Niraparib Selpercatinib Olaparib Erlotinib Erdafitinib Dabrafenib Dacomitinib Rucaparib Axitinib Panitumumab Pemigatinib Durvalumab Afatinib Entrectinib Tepotinib Alpelisib Atezolizumab + Bevacizumab Alectinib Regorafenib Cobimetinib + Vemurafenib Nilotinib Vismodegib Abemaciclib Sunitinib Nivolumab Cabozantinib Lorlatinib Talazoparib Dabrafenib + Trametinib Pembrolizumab Pertuzumab + Trastuzumab | The Drug Rediscovery Protocol (DRUP Trial) (DRUP) | Recruiting | NLD | 0 |
NCT05727176 | Phase II | Futibatinib | Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement (FOENIX-CCA4) | Recruiting | USA | ITA | ESP | AUS | 7 |
NCT03773302 | Phase III | Cisplatin + Gemcitabine Infigratinib | Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations | Terminated | USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS | 6 |
NCT04233567 | Phase II | Infigratinib | Infigratinib for the Treatment of Advanced or Metastatic Solid Tumors in Patients With FGFR Gene Mutations | Active, not recruiting | USA | 0 |
NCT01948297 | Phase I | Debio 1347 | Debio 1347-101 Phase I Trial in Advanced Solid Tumours With Fibroblast Growth Factor Receptor (FGFR) Alterations | Terminated | USA | ESP | 3 |
NCT02272998 | Phase II | Ponatinib | Ponatinib for Patients Whose Advanced Solid Tumor Cancer Has Activating Mutations Involving the Following Genes: FGFR1, FGFR2, FGFR3, FGFR4, RET, KIT. | Active, not recruiting | USA | 0 |
NCT03822117 | Phase II | Pemigatinib | Efficacy and Safety of Pemigatinib in Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207) | Terminated | USA | ITA | GBR | FRA | ESP | DEU | 5 |
NCT05510427 | Phase I | Atezolizumab + Bevacizumab + Infigratinib | Phase Ib Trial of Infigratinib In Combination With Atezolizumab And Bevacizumab for The Second-Line Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion/Amplification | Withdrawn | 0 | |
NCT05253807 | Phase II | Pemigatinib | Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Relapsed or Refractory Advanced Non-Small Cell Lung Cancer With an FGFR Alteration (FIGHT-210) | Completed | USA | ITA | FRA | ESP | DEU | 0 |
NCT05627063 | Phase I | ABSK121 | A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK121-NX in Patients With Advanced Solid Tumors | Recruiting | USA | 1 |
NCT05565794 | Phase II | Pemigatinib | Pemigatinib After Curative Local Therapy in Advanced iCCA With FGFR2 Fusion/Rearrangements | Recruiting | DEU | 0 |
NCT04601857 | Phase II | Futibatinib + Pembrolizumab | Futibatinib and Pembrolizumab Combination in the Treatment of Advanced or Metastatic Urothelial Carcinoma | Active, not recruiting | USA | FRA | ESP | 0 |